Navigation Links
Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
Date:12/17/2008

CARLSBAD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:      Abbott's exercise of its option to purchase Ibis Biosciences,
               a subsidiary of Isis. Total acquisition price will be
               $215 million.

    When:      Wednesday, December 17, 2008 at 8:30 a.m. ET / 5:30 a.m. PT

    Where:    http://www.isispharm.com

    How:       Live on the Internet.  Simply log onto our Web site listed
               above.

    Contacts:  Kristina Lemonidis
               Associate Director, Corporate Development
               (760) 603-2490

               Amy Blackley, Ph.D.
               Manager, Corporate Communications
               (760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
3. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
4. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
5. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
6. Diagnostic Imaging to Deliver Its 11th Annual Webcast of Key Events Taking Place at RSNA 2008
7. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
8. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
10. Cepheid to Webcast Upcoming Financial Presentations
11. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... Linda, Ca (PRWEB) , ... August 09, 2017 ... ... exosomes for regenerative medicine applications in the clinic is here. The team at ... EVs present in conditioned medium for clinical studies. , Dr. Travis Antes, ...
(Date:8/10/2017)... USA (PRWEB) , ... August 09, 2017 , ... ... partnered with four international biomedical optics laboratories — the Wellman Center for Photomedicine, ... Medical Laser Center Lübeck and the Beckman Laser Institute at University of California, ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... market news outlet had initiated coverage on Next Group Holdings, Inc. and see's ... consumer markets geared toward those that cannot engage in traditional banking services. According ...
(Date:8/8/2017)... ... August 08, 2017 , ... HumanZyme Inc., a leading supplier ... announced the launch of HumanKine® Interferon beta (IFN beta) expressed from ... activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):